Oncolytics Biotech is seeking orphan-drug status for a virus-based treatment for gastric cancer

Brad Thompson, CEO of Oncolytics Biotech, was thrilled to see CBS’ 60 Minutes bring attention to virus-based cancer treatments a couple weeks back, in a report focused on an engineered polio virus being developed at Duke University to treat glioblastoma, a deadly form of brain cancer. But Thompson also understands all too well the challenges of bringing these viruses to market, having guided his company through a sometimes brutal and public quest to develop a treatment that’s similar to the Duke approach.